Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1, Randomized Controlled Dose Escalation, Safety and Immunogenicity Study of Intramuscular Norovirus GI.1/GII.4 Bivalent Virus-Like Particle (VLP) Vaccine Adjuvanted With Monophosphoryl Lipid A (MPL) and Aluminum Hydroxide [Al(OH)3] in Adults

NCT01168401 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT01168401
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01168401 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1, Randomized Controlled Dose Escalation, Safety and Immunogenicity Study of Intramuscular Norovirus GI.1/GII.4 Bivalent Virus-Like Particle (VLP) Vaccine Adjuvanted With Monophosphoryl Lipid A (MPL) and Aluminum Hydroxide [Al(OH)3] in Adults
Lead sponsor
Takeda
Phase
Phase 1
Overall status
Completed
Start date
September 3, 2010
Completion date
January 9, 2013
Enrollment
102 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

gastroenteritis